Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer.

Ujjwal M MahajanElisabetta GoniEnno LanghoffQi LiEithne CostelloWilliam GreenhalfStephan KrugerSteffen OrmannsChristopher M HalloranPaula GanehManuela MarronFelix LämmerhirtYue ZhaoGeorg BeyerFrank-Ulrich WeissMatthias SendlerChristiane J BrunsThomas KohlmannThomas KirchnerJens WernerJan G D'HaeseMichael von Bergwelt-BaildonVolker HeinemannJohn P NeoptolemosMarkus W BüchlerClaus BelkaStefan BoeckMarkus M LerchJulia Mayerle

Published in: JNCI cancer spectrum (2019)

Adjuvant gemcitabine is less effective in pancreatic ductal adenocarcinoma with high CatD expression, and thus CatD could serve as a marker for biomarker-driven therapy.

Keyphrases

poor prognosis
early stage
binding protein
locally advanced
radiation therapy